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ABSTRACT 
A minimally-invasive alternative to surgical biopsies is a liquid biopsy (LB), a technique that has recently 
revolutionized the management of a number of tumors. One potential target biomarker of LB is cell-free 
DNA (cfDNA), which can act as a very sensitive indicator for certain tumors. Currently, clinical efforts are 
focused on increasing the quality of the cfDNA isolated for analysis. 
The present study compares the efficiency of isolation by four commercial kits: QuickGeneMINI8L (Kurabo), 
Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit 
(Qiagen). In each case, cfDNA was isolated from three plasma samples and one serum sample. 
Available method for the isolation give the ability to enrich optimal diagnostic quantity of cfDNA. cfDNA 
can be successfully separated using all investigated kits. The greatest efficiency was demonstrated by 
the QIAamp MinElute ccfDNA Kit (Qiagen) and cfKapture 21 (MagBio). Large amounts of cell-free DNA 
can be successfully isolated from small volumes of plasma. 
Key words: liquid biopsy, breast cancer, cell-free DNA
Med Res J 2020; 5 (2): 92–99
Corresponding author: 
Katarzyna Boguszewska-Byczkiewicz, 
Department of Surgical Oncology, 
Copernicus Provincial Multidisciplinary 
Centre of Oncology and Traumatology, 
93–513 Lodz, Paderewskiego 4, Poland 
e-mail: k.boguszewska@kopernik.lodz.pl  
Medical Research Journal 2020; 
Volume 5, Number 2, 92–99
10.5603/MRJ.a2020.0021
Copyright © 2020 Via Medica
ISSN 2451–2591
Introduction
Liquid biopsy (LB) is a minimally-invasive diag-
nostic method based on the isolation of biomarkers 
dissolved in body fluids such as blood, cerebrospinal 
fluid, pleura effusion, sputum, saliva or seminal fluid [1]. 
By analyzing various circulating molecular biomarkers, 
such as circulating tumor cells (CTCs), cell-free DNA 
(cfDNA), exosomes, proteins and microRNA(miRNA), 
it is possible to achieve early diagnoses of a number 
of diseases. 
 One of the most promising of these biomarkers is 
cell-free DNA (cfDNA), first described in 1948 [2]. The 
cfDNA profile corresponds with the metastatic model 
and disease progression; it can also reflect co-morbidity 
and resistance mechanisms, as well as the complete 
cancer gene expression profile and tumor staging [3–9]. 
cfDNA also includes circulating tumor DNA (ctDNA)  re-
ferred to as the tumor code in the blood [10]; however, 
the ctDNA is mixed with a wide range of cfDNA from 
various sources and is hence difficult to detect clearly. In 
line with the recent surge of interest in the development 
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of innovative technologies to detect cfDNA in LB, the 
present study evaluates four commercially-available 
cfDNA extraction kits as candidates for improved cfDNA 
isolation techniques.
In 2016, cfDNA testing was given FDA approval for 
clinical usage. Unfortunately, the current high cost of 
LB technology, and the associated technical challenges 
in cfDNA isolation, limit its clinical adoption. However, 
LB offers great potential for daily use as it requires little 
time and resources to perform, and possesses broad 
diagnostic potential. 
Aim
The present study compares the efficiency of four 
cfDNA isolation kits in patients with breast cancer to de-
termine which offers the most efficient cfDNA isolation; 
it also determines whether serum or plasma provides 
the greatest quantities of cfDNA.
Material and methods
Three patients with breast cancer were enrolled in 
the study; they were selected from patients hospitalized 
in the Department of Surgical Oncology, Copernicus 
Memorial Hospital, Lodz, Poland. The medical records 
of those patients, including the age of breast cancer 
removal, type of surgery, size of tumor, histological 
type of cancer, hormone receptor profile, grading, TNM 
staging and lymph node involvement, were reviewed 
retrospectively. Patient baseline characteristics are 
presented in Table 1. 
All participants gave written informed consent to 
take part in the study. Approval for the study was giv-
en by the local ethics committee (study number RNN/ 
/345/15/KE dated 15.12.2015).  
Patient 3
The patient was 84 years old at the time of the inves-
tigation, with lobular type breast cancer on the left side, 
G2, with no ductal carcinoma in situ (DCIS) component, 
diameter 1.8 cm, classified as T1NO, after mastectomy. 
Human epidermal growth factor receptor 2 (HER2) 
status was negative, estrogen receptor (ER) status 
was positive (100% of expression) and progesterone 
receptor (PR) status was positive (90% of expression). 
Patient 17
The patient was 54 years old at the time of the in-
vestigation, with no special type (NST) breast cancer 
on the right side, G2 with no DCIS component, diame-
ter 1.1 cm, classified as T1NO, after mastectomy with 
sentinel lymph node biopsy (SLNB). HER2 status was 
negative, ER status was negative (0% of expression), 
PR status was negative (0% of expression).
Patient 19
The patient was 69 years old at the time of the 
investigation, with NST breast cancer on the left side, 
G2, with DCIS component, diameter 2 cm, classified as 
T1N2 after breast conservation therapy; the patient had 
undergone axillary lymph node dissection.HER2 sta-
tus was negative, ER status was positive, PR status 
was positive. The reason why we have chosen those 
particular 3 patients is because they fulfill the criteria 
of TNM class when it comes to all dimensions (size, 
lymph nodes and metastases). 
Method
Blood samples were obtained from the peripheral 
veins of all participants and frozen at –80°C. Each serum 
sample was numbered according to the participating 
patient. The following commercial cfDNA isolating kits 
were analyzed:  QuickGene-Mini8L (Kurabo, Japan), 
cfKapture 21 Kit (200–400 μL) (MagBio Genomics, 
USA), Maxwell RSC ccfDNA Plasma Kit (Promega, 
USA), QIAamp MinElute ccfDNA (Qiagen, Germany). 
Laboratory testing was performed in the Laboratory of 
Personalized Medicine and Laboratory of Biotechnol-
ogy, BioNanoPark in Lodz.
A.  Isolation of cfDNA from serum sample number 3: 
 cfDNA was isolated from serum sample 3 using two 
kits: QuickGeneMINI8L from Kurabo and the QIAamp 
MinElute ccfDNA Kit from Qiagen. 
B.  Isolation of cfDNA serum sample number 17: 
 cfDNA was isolated from serum sample 17 using 
three kits: the aMaxwell RSC (Promega) cfDNA 
Plasma Kit, the cfKapture 21 Kit (MagBio) and the 
QIAamp MinElute ccfDNA Kit (Qiagen).
C.  Isolation of cfDNA serum sample number 19:
 cfDNA was isolated from serum sample 19 using four 
kits: QuickGeneMINI8L (Kurabo), Maxwell RSC cfD-
NA Plasma Kit (Promega), cfKapture 21 Kit (MagBio) 
and QIAamp MinElute ccfDNA Kit (Qiagen). 
D.  Comparison of cfDNA isolation from plasma and 
serum sample from patient number 19: 
 Isolation was carried out using two kits: the Maxwell 
RSC cfDNA Plasma Kit (Promega) and cfKapture 
21 Kit (MagBio). Plasma and serum samples were 
both taken from patient number 19. 
In all cases, the obtained cfDNA fragments were 
analyzed by automated gel electrophoresis on a Tape 
Station 2200( Agilent) using D1000 High Sensitive 
Screen Tape. 
94
MEDICAL RESEARCH JOURNAL 2020. vol. 5. no. 2
www.journals.viamedica.pl/medical_research_journal
Table 1. Patient profiles
Patient 
number
Tumor type/
/DCIS 
component
TNM/G Tumor size
[cm]
side HER/
/ER/PR
Operation type
3 Lobular/no T1N0/G2 1.8 left –++/
/luminal A
mastectomy
17 NST/no T1N0/G2 1.1 right – – –/
/triple
 negative
mastectomy
19 NST/no T1N2/G2 2.0 left –++  Breast 
conservation 
therapy (BCT)
Table 2.  A comparison of the tested kits
The name of a kit Purification method Buffer volume
[µL]
Starting material volume 
[mL]
QuickGeneMINI8L (Kurabo) DNA affinity columns 100.0 3.0
QIAamp MinElute ccfDNA Kit  
(Qiagen)
magnetic beads with on-
column purification
60.0 1.0
Maxwell RSC cfDNA Plasma Kit 
(Promega)
magnetic beads 60.0 1.0
cfKapture 21 Kit (MagBio) magnetic beads 50.0 0.28
Summary of characteristics of all kits used for iso-
lation is shown in Table 2. 
Results
A.  For sample 3, a high number of cfDNA fragments 
about 180 bp length were observed; however, only 
for the QIAamp MinElute ccfDNA kit. The isolated 
cfDNA  is presented in Figure 1. 
B.  For sample number 17, cfDNA was isolated suc-
cessfully with all of the kits. The largest amount of 
cfDNA was obtained by the Qiamp MinElute ccfD-
NA Kit from 1 ml of starting material. However, the 
highest yield, i.e. the greatest amount of cfDNA per 
given volume of starting material, was obtained by 
the cfKapture 21 Kit, as this only required 280 μL of 
starting material. Figure 2 presents the cfDNA isolat-
ed from sample number 17 by three cfDNA isolation 
kits: A1 — cfKaptur 21 Kit; E1 — QIAamp MinElute 
ccfDNA Kit; F5 — Maxwell RSC cfDNA Plasma Kit. 
The efficacy of the isolation method is reflected by 
cfDNA concentration related to cfDNA fragment 
size. The horizontal axis and vertical axis represent 
product size and peak height of DNA concentration, 
respectively. 
C.  For sample number 19, the greatest amount of 
cfDNA was obtained using the Qiamp MinElute 
ccfDNA Kit (i.e. from 1 mL material), while the high-
est efficiency was obtained by the cfKapture 21 Kit 
(i.e. from 280 μL material). The isolated cfDNA  is 
presented in Figure 3. 
D.  A high level of genomic DNA contamination was ob-
served during cfDNA isolation from serum samples, 
evidenced by the presence of additional products 
longer than 180 bp. This is confirmed by the isolation 
results obtained by the two kits used. In the case of 
cfDNA isolation from plasma, a single peak character-
istic of the size of cfDNA was obtained . The isolated 
cfDNA  is presented in Figure 4 and Figure 5.
Discussion
The concept of circulating tumor cells was first 
proposed by Ashworth in 1869 following the iden-
tification of tumor cells in the peripheral blood of 
a patient with metastatic disease. However, the 
relationship between cfDNA and malignant disease 
was only established in 1975 [16]. In recent years, 
a large number of studies have attempted to elimi-
nate the background interference generated by large 
amounts of cfDNA from other sources: the concen-
tration of total cfDNA in healthy individuals ranges 
from 0 to 100 ng/mL, and this value can be as high 
as 1000 ng/mL in cancer patients [17, 18]. cfDNA is 
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A2
D1
Figure 1. Electrophoresis of cfDNA isolated from sample number 3 by Agilent 2200 TapeStation 2200. A2-
QuickGeneMINI8L(Kurabo), D1-QIAamp MinElite ccfDNA Kit(Qiagen). The observed bands are described in more detail in 
Table 3. and Electropherograms of cfDNA isolation products (A2-Kurabo, D1-Qiagen), obtained with Tape Station 2200 (Agilent)
Figure 2. Electrophoresis of cfDNA isolated from sample no. 17 by Agilent 2200 TapeStation 2200. A1 – cfKapture 21 Kit; 
E1- QIAamp MinElute ccfDNA Kit; F5- Maxwell RSC cfDNA Plasma Kit. The observed bands are described in more detail 
in Table 3. and Electropherograms for cfDNA isolated fragments (A1 — cfKapture 21 Kit; E1 — QIAamp MinElute ccfDNA 
Kit; F5 — Maxwell RSC cfDNA Plasma Kit), obtained using an Agilent TapeStation 2200
A1
E1
F5
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Figure 3. Electrophoresis of cfDNA isolated from sample no. 19 by Agilent 2200 TapeStation 2200: B2-QuickGeneMINI8L; 
G5- Maxwell RSC cfDNA Plasma Kit; B1 — cfKapture 21 Kit: F1— QIAamp MinElute ccfDNA Kit. The observed bands are 
described in more detail in Table 3. and Electropherograms of cfDNA isolated from sample no. 19 using the following 
kits: B2-QuickGeneMINI8L; G5 — Maxwell RSC cfDNA Plasma Kit; B1 — cfKapture 21 Kit: F1 — QIAamp MinElute 
ccfDNA Kit (TapeStation 2200, Agilent). The efficacy of the isolation method is determined by cfDNA concentration 
related to cfDNA fragment size. The horizontal axis and vertical axis represent the product size and peak height of DNA 
concentration, respectively
predominantly of hematopoietic origin, with cfDNA 
from non-hematopoietic cells being shorter [19, 20].
This preliminary study is intended as a segue to fur-
ther analyses of isolated ctDNA. Although the approach 
is expensive, it has established a firm foundation for 
liquid biopsy (LB) as a minimally-invasive diagnostic 
tool with strong potential to predict clinically-important 
changes. Analyses performed on genetic material 
isolated from neoplastic cells are highly accurate and 
have a low false-negative rate. The presence of ctDNA 
can be indicative of even very low levels of potent on-
cogenic cells. 
Our findings may play a significant role in opening 
this area of study. Previous studies have addressed the 
standardization of ctDNA measurement and the further 
improvement of cfDNA extraction kits, and have attempt-
ed to simplify longitudinal monitoring. The findings have 
yielded clinically-significant information regarding the 
monitoring of ctDNA quantity and accessibility. 
In addition to comparing cfDNA isolation kits, the 
present study also compares the suitability of plasma 
and serum as bases for ctDNA quantification. While ctD-
NA is typically quantified by digital PCR (dPCR) specific 
for the mutations detected in the tumor tissues [9], am-
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Figure 4. Electrophoresis of cfDNA isolated from sample 
no. 19 by Agilent 2200 TapeStation 2200. The following 
cfDNA were assumed to be ctDNA: 184 bp in plasma (H5) 
and 211bp in serum (A6) for the Maxwell RSC cfDNA Plasma 
Kit, and 185 bp in serum (C1) for the cfKapture 21 Kit. The 
observed bands are described in more detail in Table 4
Figure 5. Electropherograms for cfDNA isolation products using the Maxwell RSC cfDNA Plasma Kit (H5 — Plasma, 
A6 — Serum), and cfKapture 21 Kit (C1 — Serum, E1 — Plasma) (TapeStation 2200). The efficacy of the isolation method 
is reflected by cfDNA concentration related to cfDNA fragment size. The horizontal axis and vertical axis represent product 
size and the peak height of DNA concentration, respectively
H5
C1
A6
E1
plification refractory mutation systems (ARMSs), droplet 
digital PCR (ddPCR), and next-generation sequencing 
(NGS) can also be used [11]. In our analysis, cfDNA 
from the peripheral blood was enriched by size-based 
separation: a procedure that concentrates the propor-
tion of ctDNA within a sample based on fragment size 
[15]. By following this approach, a significantly higher 
proportion of tumor ctDNA is detected by primers that 
target amplicons shorter than 100 bp and is directly 
correlated with the increase of ctDNA concentration; in 
addition, while ctDNA fragments longer than 10,000 bp 
are likely to originate from necrotic cells, those shorter 
than 1000 bp, particularly 180 bp or multiples of this 
size, tend to be from apoptotic cells [12–14].  
The amount of cfDNA and the length of ctDNA 
fragments can be used to predict progression-free 
survival and overall survival in patients with breast 
cancer. It has been demonstrated that both cfDNA 
fragment size and high cfDNA levels pre-treatment are 
associated with shorter progression-free survival and 
overall survival; in addition, pre-treatment cfDNA levels 
could independently predict prognosis for both progres-
sion-free survival and overall survival [21, 22]. Studies of 
metastatic melanoma treated with immune checkpoint 
inhibitors found lower ctDNA concentration at baseline 
to be associated with shorter progression-free surviv-
al, and for the concentration to increase with tumor 
burden during treatment [23]. Although the amount 
of isolated cfDNA depends on the efficiency of the ex-
traction method, a comparable influence is exerted by 
pre-analytical factors such as type of blood collection 
tube, centrifugation speed and storage temperature. 
Pre-analytical variables can also influence the release 
of non-mutated DNA from leucocytes, resulting in the 
dilution of the ctDNA fraction [24].
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Table 3. Sample placement on the gel (Fig. 1, 3, 5) and a comparison of DNA concentration and fragment sizes 
Well  
number
Sample 
number
The name of the cfDNA isolation kit 
used
DNA concentration
[pg/µL]
Fragment size [bp]
A2 3 QuickGeneMINI8L (Kurabo) 26.8 N/A
D1 3 QIAamp MinElute ccfDNA Kit (Qiagen) 59.8 181
A1 17 CfKapture 21 Kit (MagBio) 47.7 167
E1 17 QIAamp MinElute ccfDNA Kit (Qiagen) 107.0 177
F5 17 Maxwell RSC cfDNA Plasma Kit (Promega) 32.8 185
B2 19 QuickGeneMINI8L (Kurabo) 29.9 135
G5 19 Maxwell RSC cfDNA Plasma Kit (Promega) 24.7 185
B1 19 CfKapture 21 Kit (MagBio) 85.9 172
F1 19 QIAamp MinElute ccfDNA Kit (Qiagen) 93.9 179
Table 4. Sample placement on the gel (Fig. 7) and a comparison of DNA concentration and fragment sizes
Well
number
Sample type The name of the cfDNA isolation kit used DNA
Concentration
[pg/µL]
Fragment
size [bp]
H5 Plasma Maxwell® RSC cfDNA Plasma Kit 25.4 184
A6 Serum 105.0
104.0
89.6
211
408
594
C1 Serum cfKapture™ 21 Kit 439.0
378.0
185
365
E1 Plasma 30.7 164
The kits used in the present study differ with regard to 
the amount of starting material required. cfDNA has a short 
half-life of less than two hours and is cleared through 
the liver and kidneys; hence, failure of these organs 
can affect cfDNA clearance in cancer patients [25, 26]. 
Changes in the numbers of chromosomal regions 
have been detected in plasma tumor-specific cfDNA as 
copy number aberrations, and these can be used to 
compute a genomic copy number instability score [27].  
The use of cfDNA offers greater clarity regarding tumor 
information than circulating (CTC) tumor cell analysis 
[28, 29]. It is important to note that the mass of the 
detected tumors would typically range from 0.1 g to 
1 g, small enough to be present in asymptomatic 
individuals [30].
The quantity of cfDNA that can be extracted from plas-
ma can vary depending on the efficiency of the chosen 
extraction method [30]. In the present study, cfDNA levels 
were established in treatment-naïve samples.  Recently, 
cfDNA analysis has allowed a non-invasive method for 
the identification of resistance mutations selective for 
treatment method. cfDNA mutation may well serve as 
an early predictor of response to standard chemother-
apy, and the presence of immune checkpoint inhibitors 
(immunotherapy) such as PD-1, PDL-1, LAG3, TIMI-3. 
Conclusion
Malignant neoplasms release significant amounts of 
ctDNA into the circulatory system as a result of necrosis 
and apoptosis. Most of these fragments are in the range 
of 160–180 bp. These ctDNA constitutes over 90% of 
total circulating cfDNA. However, the amount of isolat-
ed cfDNA ranges from 10 to 100 ng/mL. It is therefore 
important to develop an efficient isolation method. The 
present study compares the ability of selected kits to 
isolate total cfDNA, with the aim of eventually developing 
a method for detecting ctDNA in patients at an early 
stage of cancer. 
The study group included a small number of patients 
differing in terms of age distribution, histological type of 
breast cancer, estrogen receptor (ER) and progester-
one receptor (PR) expression status, as well as axillary 
lymph node metastasis and type of surgery performed: 
i.e. BCT vs. mastectomy. Nevertheless, the group was 
homogenous with respect to histological malignancy 
grade, this being G2, T1 in the TNM-staging system: 
tumor diameter 1–2 cm, no distant metastases(M0), 
HER2(–) negative. 
Our study confirms that that cfDNA can be success-
fully isolated using the following kits: QuickGene-Mini8L 
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(Kurabo, Japan), Catch-cfDNASerum/Plasma Kit 
(CatchGene, China), cfKapture 21 Kit (200–400 μL) 
(MagBio Genomics, USA), Maxwell RSC ccfDNA Plas-
ma Kit (Promega, USA) and QIAamp MinElute ccfDNA 
(Qiagen, Germany). Of these, the greatest efficiency 
was demonstrated by the QIAamp MinElute ccfDNA Kit 
(Qiagen) for samples 3 and 17, and cfKapture 21 for 
sample 19. 
The efficiency of cfDNA isolation from plasma and 
serum samples were compared by the use of the 
Maxwell RSC cfDNA Plasma Kit and the cfKapture 
21 Kit. A high level of genomic DNA contamination was 
observed in the serum samples, as evidenced by the 
presence of additional isolation fragments with more 
than 180 bp, while a single peak characteristic of cfDNA 
was observed in the plasma.
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